Teligent (NASDAQ:TLGT) released its quarterly earnings results on Friday. The company reported ($0.23) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.05), MarketWatch Earnings reports. The business had revenue of $7.45 million during the quarter. Teligent had a negative return on equity of 682.10% and a negative net margin of 38.13%.
NASDAQ TLGT traded down $0.01 during trading hours on Friday, reaching $0.40. The company’s stock had a trading volume of 229,008 shares, compared to its average volume of 194,116. The firm has a market capitalization of $22.09 million, a price-to-earnings ratio of -0.85 and a beta of 2.09. Teligent has a 1-year low of $0.19 and a 1-year high of $1.09. The company’s 50-day moving average is $0.37 and its two-hundred day moving average is $0.45.
Separately, ValuEngine raised Teligent from a “hold” rating to a “buy” rating in a report on Friday, March 13th.
Teligent, Inc, a specialty generic pharmaceutical company, develops, manufactures, markets, and sells generic topical, branded generic, and generic injectable pharmaceutical products in the United States and Canada. It offers generic pharmaceutical products in topical, injectable, complex, and ophthalmic dosage forms.
Recommended Story: Risk Tolerance and Your Investment Decisions
Receive News & Ratings for Teligent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teligent and related companies with MarketBeat.com's FREE daily email newsletter.